GLP-1 drugs such as tirzepatide (Mounjaro), semaglutide (Ozempic, Wegovy), and liraglutide (Saxenda) deliver major weight-loss benefits but leave unanswered questions about long-term safety and fairness in access. Credit: Shutterstock Three new Cochrane reviews report that GLP-1 drugs can lead to meaningful weight loss, although the strong involvement of pharmaceutical companies in many studies raises concerns. The World Health Organization (WHO) requested these reviews to help shape upcoming